Related references
Note: Only part of the references are listed.Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
V Guarneri et al.
ESMO OPEN (2022)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan et al.
CLINICAL BREAST CANCER (2021)
Dissecting the biological heterogeneity of HER2-positive breast cancer
Francesco Schettini et al.
BREAST (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci et al.
CELLS (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
P. F. Conte et al.
ANNALS OF ONCOLOGY (2021)
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
Fanny Ledys et al.
CANCERS (2021)
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
Jose Manuel Perez-Garcia et al.
LANCET ONCOLOGY (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
C. Saura Manich et al.
ANNALS OF ONCOLOGY (2021)
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB).
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial
Anna van der Voort et al.
JAMA ONCOLOGY (2021)
Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
Raghuveer Kavarthapu et al.
CANCERS (2021)
Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
Guoshuang Shen et al.
FRONTIERS IN ONCOLOGY (2021)
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam et al.
NPJ BREAST CANCER (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F. Rimawi et al.
CLINICAL CANCER RESEARCH (2020)
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2020)
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?
Mariana Brandao et al.
CLINICAL CANCER RESEARCH (2020)
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Fara Braso-Maristany et al.
NATURE COMMUNICATIONS (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys
Kazuyoshi Kumagai et al.
CANCER SCIENCE (2020)
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Eva Ciruelos et al.
CLINICAL CANCER RESEARCH (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo L. B. Costa et al.
NPJ BREAST CANCER (2020)
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Olga Martinez-Saez et al.
BREAST CANCER RESEARCH (2020)
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Gaia Griguolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
197TiPPhase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer
F André et al.
ANNALS OF ONCOLOGY (2019)
Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Phase II CONTROL trial.
Carlos Hernando Barcenas et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
Pier Franco Conte et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl et al.
LANCET (2019)
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)
Stephen Chia et al.
ONCOLOGIST (2019)
Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
Ki-Tae Hwang et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
Nehad M. Ayoub et al.
BREAST CANCER-TARGETS AND THERAPY (2019)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients
Emanuela Risi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+Breast Cancer Subtypes
Spencer S. Watson et al.
CELL SYSTEMS (2018)
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2018)
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Ryan L. Powles et al.
JAMA ONCOLOGY (2018)
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
P. Conte et al.
ANNALS OF ONCOLOGY (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Optimal treatment of early stage HER2-positive breast cancer
Sonia Pernas et al.
CANCER (2018)
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst et al.
LANCET ONCOLOGY (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S. M. Swain et al.
ANNALS OF ONCOLOGY (2018)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin et al.
LANCET ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli et al.
JAMA ONCOLOGY (2017)
The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives
R. L. B. Costa et al.
CANCER TREATMENT REVIEWS (2017)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U. A. Nitz et al.
ANNALS OF ONCOLOGY (2017)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini et al.
BREAST CANCER RESEARCH (2017)
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
Q. Wang et al.
ONCOGENE (2016)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2016)
Antibody drug conjugates
Ray Bakhtiar
BIOTECHNOLOGY LETTERS (2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel et al.
CANCER CELL (2016)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L. McArthur et al.
CLINICAL CANCER RESEARCH (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Anthony Ferrari et al.
NATURE COMMUNICATIONS (2016)
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Lance D. Miller et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden et al.
BMC MEDICAL GENOMICS (2015)
Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Carlos Acevedo-Gadea et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al.
LANCET ONCOLOGY (2014)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Mario Giuliano et al.
BREAST CARE (2013)
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response
Lara Hannesdottir et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
Katherine L. Pogue-Geile et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
M. Hauglid Flageng et al.
BRITISH JOURNAL OF CANCER (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Complex prolactin crosstalk in breast cancer: New therapeutic implications
Kristopher C. Carver et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
Suleiman Massarweh et al.
CANCER RESEARCH (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Membrane receptors for steroid hormones: Signal transduction and physiological significance
I Nemere et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
G Konecny et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
